Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20592-20603

  Xu, Benling ^a,b   Yuan, Long ^b   Gao, Quanli ^b   Yuan, Peng ^b   Zhao, Peng ^c   Yuan, Huijuan ^d   Fan, Huijie ^a   Li, Tiepeng ^b   Qin, Peng ^b   Han, Lu ^b   Fang, Weijia ^c   Suo, Zhenhe ^a,e  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colorectal cancer; PD 1; T cell exhaustion; Tim 3

Indexed keywords

GAMMA INTERFERON; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; UNCLASSIFIED DRUG; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PDCD1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER INFILTRATION; CANCER STAGING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNE DYSREGULATION; MAJOR CLINICAL STUDY; MALE; PARANEOPLASTIC SYNDROME; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; COLORECTAL TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TRANSFECTION;

EID: 84940203048     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4112     Document Type: Article

References (40)

1. Schirrmacher V, Fournier P and Schlag P. Autologous tumor cell vaccines for post-operative active-specifific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert review of vaccines. 2014; 13:117-130.
2. Volonte A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G and Maccalli C. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. Journal of immunology. 2014; 192:523-532.
3. Izhak L, Ambrosino E, Kato S, Parish ST, O'Konek JJ, Weber H, Xia Z, Venzon D, Berzofsky JA and Terabe M. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer research. 2013; 73:1514-1523.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960-1964.
5. Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y, Wang P and Du Z. Prognostic value of tumor-infifiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PloS one. 2014; 9:e94376.
6. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G and Ferrari C. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010; 138:682-693, 693 e681-684.
7. Cai G, Nie X, Li L, Hu L, Wu B, Lin J, Jiang C, Wang H, Wang X and Shen Q. B and T lymphocyte attenuator is highly expressed on intrahepatic T cells during chronic HBV infection and regulates their function. J Gastroenterol. 2013; 48:1362-1372.
8. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ and Jang KY. Tumor infifiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PloS one. 2013; 8:e82870.
9. Chemnitz JM, Lanfranco AR, Braunstein I and Riley JL. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. Journal of immunology. 2006; 176:6603-6614.
10. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK and Blazar BR. Coexpression of Tim-3 and PD-1 identififies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117:4501-4510.
11. Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG and Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013; 121:1612-1621.
12. Thoulouze MI, Sol-Foulon N, Blanchet F, Dautry-Varsat A, Schwartz O and Alcover A. Human immunodefificiency virus type-1 infection impairs the formation of the immunological synapse. Immunity. 2006; 24:547-561.
13. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL and Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007; 27:670-684.
14. Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V and Zarour HM. CD8(+) T cells specifific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer research. 2012; 72:887-896.
15. Topalian SL. safety, activity, and immune correlates of anti-pd-1 antibody in cancer. new england journal of medicine. 2012; 31:2443-2454.
16. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specifific CD8+ T cell dysfunction in melanoma patients. The Journal of experimental medicine. 2010; 207:2175-2186.
17. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, et al. Tim-3 expression defifines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. The Journal of experimental medicine. 2008; 205:2763-2779.
18. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, Gretch DR and Rosen HR. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. Journal of virology. 2009; 83:9122-9130.
19. Chaput N, Louafifi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F, Rosenzwajg M, Lemoine F, Klatzmann D and Taieb J. Identifification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut. 2009; 58:520-529.
20. Grivennikov SI, Greten FR and Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
21. Mantovani A, Allavena P, Sica A and Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-444.
22. Moon EK, Wang LC, Dolfifi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, June CH, Riley JL, Wherry EJ and Albelda SM. Multifactorial T-cell hypofunction that is reversible can limit the effificacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clinical cancer research: an offificial journal of the American Association for Cancer Research. 2014; 20:4262-4273.
23. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfifield EA, Coyle AJ, Sobel RA, Freeman GJ and Kuchroo VK. Th1-specifific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415:536-541.
24. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL and Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:5009-5014.
25. M'Hidi H, Thibult ML, Chetaille B, Rey F, Bouadallah R, Nicollas R, Olive D and Xerri L. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. American journal of clinical pathology. 2009; 132:589-596.
26. Baruah P, Lee M, Odutoye T, Williamson P, Hyde N, Kaski JC and Dumitriu IE. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology. 2012; 217:669-675.
27. Malaspina TS, Gasparoto TH, Costa MR, de Melo EF, Jr., Ikoma MR, Damante JH, Cavassani KA, Garlet GP, da Silva JS and Campanelli AP. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer immunology, immunotherapy: CII. 2011; 60:965-974.
28. Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, George AJ and Ghaem-Maghami S. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer immunology, immunotherapy: CII. 2014; 63:215-224.
29. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM and Zarour HM. PD-1 is a regulator of NY-ESO-1-specifific CD8+ T cell expansion in melanoma patients. Journal of immunology. 2009; 182:5240-5249.
30. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW and Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer research. 2011; 71:3540-3551.
31. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget. 2012; 3:1711-1724.
32. Blagosklonny MV. Immunosuppressants in cancer prevention and therapy. Oncoimmunology. 2013; 2:e26961.
33. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer biology & therapy. 2008; 7:1520-1524.
34. Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer biology & therapy. 2012; 13:1349-1354.
35. Bravo-San Pedro JM and Senovilla L. Immunostimulatory activity of lifespan-extending agents. Aging. 2013; 5:793-801.
36. Leontieva OV and Blagosklonny MV. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget. 2014; 5:12715-12727.
37. Altman JK, Sassano A and Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget. 2011; 2:510-517.
38. Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA and Martelli AM. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget. 2012; 3:1615-1628.
39. Markman B, Dienstmann R and Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 2010; 1:530-543.
40. Arai Y, Saito H and Ikeguchi M. Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation. Yonago acta medica. 2012; 55:1-9.